HDAC9 and cancer: Histone deacetylases (HDACs or KDACs), are regularly implicated in several pathologies, especially cancer, which prompted the clinical trials and FDA approvals for HDAC therapies (Fig. 4; Ho et al. 2020; Bondarev et al. 2021).